Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cardiology Device Lobbyists Focused On Reimbursement, Coronavirus, Trade Issues In Early 2020

Industry lobbyists include former legislators, key committee staffers, say lobby reports

Executive Summary

Cardiology device firms relied primarily on in-house lobbyists but also recruited external groups to sway lawmakers to adopt favorable positions on reimbursement, COVID-19, international trade and other issues from January-March 2020, says this Medtech Insight analysis.

You may also be interested in...

Advanced Imaging Companies Lobby Lawmakers On Device Servicing, Reimbursement Among Other Issues

Advanced imaging companies spent hundreds of thousands of dollars in Q1 2020 lobbying Congress on issues as diverse as the national COVID-19 response and cybersecurity issues but are most interested in resolving device servicing and remanufacturing problems.

Edwards Sees ‘Tough Time’ Ahead For TAVR Patients

The COVID-19 pandemic is severely hindering patient access to transcatheter aortic valve replacement procedures. Edwards Lifesciences, the market leader, is hopeful that TAVR volumes will recover by the end of 2020, but that will be too late for many patients.

VA Medical Supply Purchasing Reform Could Open New Doors

The US Department of Veterans Affairs is giving the VA’s four prime vendors for medical and surgical supplies more ability to directly choose suppliers as part of ongoing updates to the Medical/Surgical Prime Vendor (MSPV 2.0) program. Here’s what device manufacturers should know as the program rolls out.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts